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Abstract
Background: Spinal cord ischemic injury remains a serious complication of open surgical and endovascular
aortic procedures. Simvastatin has been reported to be associated with neuroprotective effect after spinal
cord ischemia-reperfusion (IR) injury. The aim of this study was to determine the therapeutic efficacy of
starting simvastatin after spinal cord IR injury in a rat model.
Methods: In adult Sprague-Dawley rats, spinal cord ischemia was induced using a balloon-tipped catheter
placed in the descending thoracic aorta. The animals were then randomly divided into 4 groups: group A
(control); group B (0.5 mg/kg simvastatin); group C (1 mg/kg simvastatin); and group D (10 mg/kg simvastatin).
Simvastatin was administered orally upon reperfusion for 5 days. Neurological function of the hind limbs was evaluated
for 7 days after reperfusion and recorded using a motor deficit score (MDS) (0: normal, 5: complete paraplegia). The
number of normal motor neurons within the anterior horns of the spinal cord was counted after final MDS evaluation.
Then, the spinal cord was harvested for histopathological examination.
Results: Group D showed a significantly lower MDS than the other groups at post-reperfusion day 1 and this trend was
sustained throughout the study period. Additionally, a greater number of normal motor neurons was observed in group
D than in other groups (group D 21.2 [3.2] vs. group A: 15.8 [4.2]; group B 15.4 [3.4]; and group C 15.5 [3.7]; P = 0.002).
Conclusions: The results of the current study suggest that 10 mg/kg can significantly improve neurologic outcome by
attenuating neurologic injury and restoring normal motor neurons after spinal cord IR injury.
Keywords: Neuroprotection, Simvastatin, Reperfusion injury, Thoracoabdominal aortic surgery
Background
Spinal cord ischemia remains to be the most impressive
and devastating complication following thoracoabdom-
inal aortic aneurysm (TAAR) surgery. Spinal cord ische-
mia leads to paraparesis and paraplegia, which have a
major invalidating impact on the patient’s life [1]. Re-
cently, thoracic endovascular aortic repair (TEVAR) has
seen great improvement in the treatment of patients
with thoracic aortic disease due to its decreased overall
morbidity and mortality compared with open thoracic
surgery [2]. Despite its advantages with respect to safety
issues compared with conventional open surgical repair,
TEVAR has been associated with spinal cord ischemia as
a major complication caused by endovascular coverage
or injury to the spinal cord collateral vessels [3].
The precise pathophysiology of spinal cord ischemia
after TAAR surgery is unclear and probably multifactor-
ial, including intercostal artery occlusion, spinal cord
hypoperfusion during aortic occlusion, or spinal cord re-
perfusion [4]. Therefore, to date, a variety of surgical
techniques have focused on maximizing spinal cord per-
fusion, oxygen delivery, and reducing oxygen consump-
tion to minimize risk of spinal cord ischemia. These
methods include systemic cooling or regional spinal
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cord cooling, cerebrospinal fluid (CSF) drainage, re-
anastomosis (re-joining) of intercostal arteries, moni-
toring somatosensory-evoked potentials, and distal
aortic perfusion [5]. Despite various surgical techniques,
the complete elimination of spinal cord ischemia remains
to be challenging, and the use of medical adjuncts for
spinal cord protection may be one of the preventive or
management measures of spinal cord ischemia [4]. Much
progress has been made in the development of pharmaco-
logic treatment of patients with spinal cord ischemia to
minimize neurologic sequale and improve neurologic
prognosis. To be clinically used, however, these neuropro-
tective drugs require the development of safety and phar-
macokinetic profile in humans. Currently, intravenous
high dose methylprednisolone remains a widespread
option for acute spinal cord ischemia despite its limited
efficacy and safety profile [6].
Simvastatin (Zocor®), a hydroxymethylglutaryl coenzyme-
A (HMG-CoA) reductase inhibitor and lipid-lowering drug,
has recently been recognized to possess powerful immuno-
modulatory and anti-inflammatory properties. Extensive
studies with various experimental models have established
the beneficial effects of simvastatin on ischemic-
reperfusion (IR) injury in various organs and tissues,
including intestine, heart, lungs, liver, and kidneys
[7–11]. Additionally, neuroprotective effects of sim-
vastatin have been investigated with preclinical ani-
mal models of a variety of neurologic conditions,
including stroke, and traumatic brain injury [12, 13].
The preventive effect of simvastatin on neurologic
damage prior to IR injury was demonstrated in a rat
spinal cord ischemia model [14, 15] but its treatment
effect after spinal cord IR injury has not been fully
investigated. Post-treatment studies provide greater
clinical implications than the pre-treatment study
since trauma or injury is unpredictable. Therefore,
we hypothesized that simvastatin is able to reduce
neurologic injury after spinal cord IR injury. This
study was designed to evaluate the treatment effect
of simvastatin with various doses on neurologic
damage using a rat spinal cord IR injury model.
Methods
Animal care and preparation
The experimental protocol of this study was approved by
the Institutional Animal Care and Use Committee of
Seoul National University Bundang Hospital. Animal
experiments and care were conducted in compliance with
the Guide for the Care and Use of Laboratory Animals,
published by the US National Institutes of Health. All
animals were kept at room temperature with equal light-
ing control (12-h light/12-h dark cycle) and all the surgical
procedures and post-reperfusion neurological assessment
were performed at 10 am.
Group assignment
Forty male Sprague-Dawley rats weighing 300 to 350 g aged
around 8 weeks were randomly assigned to 1 of the 4
groups before the surgical preparation. 1) A group (n = 10):
control group with 1 ml of saline; 2) B group (n = 10): 0.
5 mg/kg of simvastatin (Zocor®, Merck, Whitehouse
Station, USA) mixed with normal saline 1 ml; 3) C group
(n = 10): 1 mg/kg of simvastatin mixed with normal saline
1 ml; 4) D group (n = 10): 10 mg/kg of simvastatin mixed
with normal saline 1 ml. Besides the 4 experimental
groups, a blank control group without IR injury
(sham group, n = 10) was added for each experiment.
Daily oral administration was performed via oral gav-
age using a 16-gauge feeding needle immediate after
reperfusion injury for 5 days.
Anesthesia and surgical preparation
Anesthesia was induced in an acrylic chamber with
5 vol% isoflurane in 100% oxygen. Then, maintenance of
anesthesia was done with a facial mask of inhaled 1.0–2.
5 vol% isoflurane and oxygen flow of 2 L/min.
Rats were placed in the supine position and then the
hair in the neck and left inguinal area were shaved. The
left femoral artery was exposed for the induction of
spinal cord ischemia and the tail artery was cannulated
with a polyethylene catheter (PE-50) for heparin injec-
tion and monitoring of distal arterial pressure. The left
carotid artery was cannulated with a 20-gauge catheter
(BD Insyte, Becton Dickinson, Sandy, UT, USA) and
connected to a saline-filled external blood reservoir to
drain blood during the aortic occlusion period.
Experimental protocol (spinal cord ischemia)
Spinal cord ischemia was induced using Taira and
Marsala’s method [16] by investigators blind to the
group assignment. The left femoral artery was cannu-
lated with a 2 Fr Fogarty catheter (Fogarty Arterial
Embolectomy Catheter, Edwards Lifesciences, Irvine,
CA, USA), a balloon tipped catheter. The catheter was
inserted until it was place at descending thoracic aorta
and the tip of the catheter was placed the left subclavian
artery (about 11 cm from the insertion site). After can-
nulation, heparin 150 U was injected and the Fogarty
catheter balloon was inflated with 0.05 mL of saline.
Blood flow from the left carotid artery was simultan-
eously drained into the external reservoir to prevent
proximal hypertension by withdrawing blood during the
aortic occlusion. A successful aortic occlusion by the
Foarty catheter was confirmed by an immediate and
sustained decrease in the tail artery pressure.
After 10 min and 30 s of aortic occlusion, the Forgarty
balloon was deflated, and the drained blood was rein-
fused to the left carotid artery. After finishing the pro-
cedure, all catheters were removed and incisions were
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closed. The rats were then allowed to recover from
anesthesia and returned to their cages.
Evaluation of neurobehavioral outcome
Neurological function was evaluated with hind limbs
motor function after reperfusion by the observer who
was blinded to the group assignments using motor
deficit score (MDS) at 8 h, 1, 3, 5, and 7 days after
reperfusion.
The MDS is measured as follows: 0 = normal; 1 = the
animal walks normally, but legs are weak, and the ani-
mal cannot pull the legs if they are held by the examiner;
2 = the animal assumes normal body posture on a flat
surface and is able to walk, but there is ataxia or spasti-
city; 3 = the animal is able to walk on its knuckles, or
able to walk on the feet without proper stepping; 4 = the
animal drags its legs, but there is movement at the
knees; and 5 = the animal drags legs without significant
movements in the lower limbs and either spasticity or
flaccidity is present [17].
Histopathology
After the last neurological examination, spinal cords
were excised for histopathological examination. All rats
were anesthetized again with mask-delivered isoflurane.
The heart was exposed and the right auricle was cut
with a 23-gauge needle inserted into the left ventricle.
Heparinized saline was transcardially perfused passing
through the needle and circulated around the body flow-
ing out through the open right auricle. Spinal cord was
separated and fixed in 10% buffered formalin for 24 h
and L3–5 spinal cord segments were embedded in paraf-
fin. Transverse sections were cut and stained with
hematoxylin and eosin (H & E).
Neuronal injury was evaluated at X 200 magnification
by the blinded investigator. Each slide was examined and
the number of normal motor neurons in the anterior
horn of spinal cord (anterior to a line drawn through the
central canal perpendicular to the vertebral axis) was
counted to assess the degree of ischemic neuronal injury.
The spinal motor neuron with ischemic injury presents
characteristic morphological feature of pronounced eo-
sinophil cytoplasm, shrunken cell body, various degree
of pericellular edema, and shrunken and darkly pyknotic
nucleus. The anterior spinal cord of paraplegic animals
was significantly destroyed with normal motor neurons
reduced. The number of normal motor neurons was
counted in 3 sections for each animal and averaged [18].
Double counting was avoided by careful examining the
continuity of each cell.
Statistical analysis
Statistical analysis was performed with the SPSS 21
(IBM Inc., Chicago, IL, USA). The normality of all the
measured data was tested using Shapiro wilk test. Data
were presented as mean (SD) or median (interquartile
ranges [IQRs]). Repeated-measures ANOVA and post-
hoc Bonferroni correction was used and, at each time
point, MDS and the number of intact motor neuron
were compared using Kruskal- Wallis tests followed by
the Mann-Whitney U test. A Bonferroni correction was
used to adjust type I error rate for multiple comparisons.
The Bonferroni-adjusted P value was obtained by multi-
plying the unadjusted P value by the number of compar-
isons (i.e., 4), and was denoted by “corrected P.” A




All animals survived until the final neurological assess-
ment at the 7th day after reperfusion. Hind limbs motor
function was evaluated at 8 h, 1 d, 3 d, 5 d, and 7 d after
reperfusion using MDS; The MDSs of a sham group
(n = 10) was 0 (0) at each time point. The MDSs of the 4
experimental groups (the control group [group A] and
the three treatment groups [group B, c and D] are
shown in Table 1. When we compared the sham group
and the 4 experimental groups, there was significant dif-
ference in MDSs at each time point (P < 0.001). Re-
peated measures ANOVA identified that there is a
significant effect of time for MDS among the 4 experi-
mental groups (P = 0.001). At post-reperfusion 8 h, no
significant differences of MDS were observed among the
4 groups (3.5 [1.0] for group A, 3.0 [1.0] for group B, C
and D; P = 0.846). At post-reperfusion day 1, Group D
presented a significantly lower MDS compared with
groups A, B, and C (3.0 [1.0] for group A, 3.5 [1.0] for
group B, 4.0 [1.0] for group C and 3.0 [0] for group D;
P = 0.006); this trend was sustained throughout the study
period. There has been a significant change in MDS over
time for group D (3.0 [1.0] at 8 h, 3.0 [0] at 1 day, 2.5 [1.0]
at 3 and 5 day, 2.0 [1.0] at 7 day; P = 0.001), whereas no
change was observed in MDS overtime for other groups
during the study period.
Histopathology
The number of normal motor neuron of a sham group
(n = 10) was 35 (3.8) and it was significantly higher than
the other groups (P < 0.001 for each comparison). When
we compared the control group and the three treatment
groups, statistically significant difference was observed
in the number of normal motor neuron among the 4 ex-
perimental groups. The number of viable motor neuron
is significantly higher in group D compared with group A,
B and C (group D 21.2 [3.2] vs. group A: 15.8 [4.2]; group
B 15.4 [3.4]; and group C 15.5 [3.7]; P = 0.002, Fig. 1).
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Representative photos from each group are presented in
Fig. 2.
Discussion
In the present study, we reported the efficacy of simva-
statin treatment administered after IR injury, for the first
time in the literature. We showed that this simvastatin
treatment after IR injury significantly improves the
neurological outcome, as demonstrated by MDS and the
number of normal motor neurons in a rat spinal cord
ischemia model. Moreover, we determined that the most
effective dosage of simvastatin treatment is 10 mg/kg
simvastatin, which improved the neurologic outcome
and increased the number of normal motor neurons in
the anterior spinal cord after IR injury of the spinal
cord.
Spinal cord injury leads to the loss of motor function
in the hind limbs and a decrease in the number of
normal motor neurons, which are closely correlated with
the extent of spinal cord ischemia. Therefore, the neuro-
protective effect of simvastatin post-treatment after IR
injury was accompanied by low MDS and an increased
number of normal motor neuron in spinal cord ischemia
rats. Hwang et al., [14] investigated the pre-treatment ef-
fect of simvastatin after spinal cord ischemia, showing
that 10 mg/kg simvastatin administered orally for 5 days
before IR injury improved motor deficit index and pre-
served normal motor neurons. Gao et al., [19, 20] veri-
fied the molecular mechanism of the simvastatin
neuroprotective effect and concluded that simvastatin
inhibits neural cell apoptosis and preserved the motor
neuron function by autophagy induction. Moreover,
Saito et al., [15] investigated the treatment effect of
10 mg/kg simvastatin on hind limb motor dysfunction at
24 and 48 h after reperfusion in a rat spinal cord ische-
mia model. The current study investigated best dosage
of simvastatin (0.5 mg/kg, 1 mg/kg and 10 mg/kg) as
well as its long-term effect (7 days) after reperfusion in a
rat spinal cord ischemia model.
In addition to its preventive neuroprotective effect,
simvastatin treatment has previously been associated
with improved functional neurologic outcome in a
stroke model [21, 22]. The mechanism of statin’s neuro-
protective effect after IR injury of the brain has not been
fully elucidated to date, but seems to attribute to its
anti-inflammatory and antioxidant effect [23]. These
favorable CNS environments may create a potential
microenvironment facilitating both regeneration of dam-
aged neurons and remyelination of demyelinated axons
after IR injury [21, 22]. Post-treatment of atorvastatin
was also investigated in efforts to improve the recovery
of motor functions after spinal cord injury and the at-
tenuation of early inflammatory events by atorvastatin
seemed to reduce secondary injury [24]. On the con-
trary, a few studies failed to observe the treatment effi-
cacy of simvastatin after cervical or thoracic spinal cord
ischemia [25, 26]. The possible explanation of these dif-
ferences may be explained by the degree of severity of
Table 1 Motor Deficit Score (MDS) of the sham, control and treatment groups











8 h 0 (0) ¶ 3.5 (1.0) 3.0 (1.0) 3.0 (1.0) 3.0 (1.0) < 0.001
1 day 0 (0) ¶ 3.0 (1.0) 3.5 (1.0) 4.0 (1.0) 3.0 (0)* < 0.001
3 day 0 (0) ¶ 4.0 (1.0) 4.0 (1.0) 4.0 (1.0) 2.5 (1.0)* † ‡ < 0.001
5 day 0 (0) ¶ 4.0 (1.0) 4.0 (1.0) 4.0 (1.0) 2.5 (1.0)* † ‡ < 0.001
7 day 0 (0) ¶ 3.5 (1.0) 4.0 (1.0) 4.0 (1.0) 2.0 (1.0)* † ‡ < 0.001
0 = normal; 1 = the animal walks normally, but legs are weak, and the animal cannot pull the legs if they are held by the examiner; 2 = the animal assumes normal
body posture on a flat surface and is able to walk, but there is ataxia or spasticity; 3 = the animal is able to walk on its knuckles, or able to walk on the feet without
proper stepping; 4 = the animal drags its legs, but there is movement at the knees; and 5 = the animal drags legs without significant movements in the lower limbs and
either spasticity or flaccidity is present. Data are presented as median (IQR). Group S: sham group; Group A: control group; Group B: 0.5 mg/kg simvastatin group; Group
C: 1 mg/ kg simvastatin group; Group D: 10 mg/kg simvastatin group
¶: P < 0.001 compared with Group A,B, C and D; *: P < 0.0125 compared with Group C; †: P < 0.0125 compared with Group B; ‡: P < 0.0125 compared with Group A;
Fig. 1 Normal motor neuron numbers in the anterior spinal cord.
The number of normal motor neuron is significantly higher in group
D than group B and C. Data are presented as mean (SD). Group S:
sham group; Group A: control group; Group B: 0.5 mg/kg simvastatin
group; Group C: 1 mg/ kg simvastatin group; Group D: 10 mg/kg
simvastatin group. * P = 0.002 compared with group A, B and C.
† P = 0.002 compared with group A, B, C and D
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spinal cord ischemia, since these two studies used direct
traumatic or contusion spinal cord ischemia model ra-
ther than an IR injury model.
The mechanism of IR injury includes damage induced
by both ischemia and reperfusion. During the ischemic
phase, inadequate oxygen supply and accumulation of
toxic metabolites result in neuronal necrosis [27]. Dur-
ing the reperfusion stage, re-establishment of oxygen
supply causes reactive oxygen species (ROS) formation
and subsequent re-established blood supply facilitates
neutrophils recruitment with immunologic cascade.
During this process, various cytokines and growth fac-
tors aggravate tissue damage [27]. Therefore, pharmaco-
logical treatment of IR injury can prevent ischemic
injury as well as the production of ROS with inflamma-
tory cytokine. The mechanisms of neuroprotective effect
of simvastatin after IR injury are not well recognized,
but may be explained by anti-inflammatory effect, anti-
oxidant effect, and vascular actions. First, simvastatin
modulates endothelial nitric oxide synthase (eNOS),
which improves cerebral blood flow in cells [28, 29].
Second, simvastatin has been known to reduce vascular
inflammation, oxidative stress, and cytokine responses
that occur during ischemia and reperfusion by reducing
the induction of inducible nitric oxide synthase (iNOS),
interleukin-1, and tumor necrosis factor-α in astrocytes
and macrophages [30, 31].
Simvastatin was chosen for this study since simvastatin
has a superior neuroprotective property compared with
other statins due to a greater lipophilic property and
more capability of crossing blood brain barrier [22]. The
result of this study suggested that post-conditioning with
10 mg/kg simvastatin was neuroprotective after spinal
cord IR injury, whereas 0.5 mg/kg and 1 mg/kg were not
effective for the restoration of motor function. Simva-
statin 0.5 mg/kg was based on the upper limit of 40 mg/
day, considering its absorbed fraction (60–80%) and bio-
availability (5%) with oral administration [32]. Simva-
statin 1 mg/kg corresponds to 60–80 mg/day for the
treatment of stroke patients [33]. Ischemic tolerance
may vary depending on the species and brain region [34]
and 10 mg/kg simvastatin was demonstrated to have
preventive effect after IR injury of the spinal cord [14,
15], lung [8] and intestine [10]. Further studies are ne-
cessary to determine the optimal dosage for the applica-
tion of human spinal cord IR injury.
This is the first in vivo experiment of simvastatin
treatment after spinal cord IR injury with respect to the
restoration of motor neuron and its function in a rat
model. However, this has a few limitations to be consid-
ered. First, the result of this study suggested the neuro-
logic outcome without the elucidation of the associated
pathway or receptor. The mechanisms underlying the
above-mentioned effects have not been fully elucidated
and its anti-inflammatory, antioxidant effect and vascu-
lar actions seems to be responsible for this finding [28–
31]. Second, larger doses could be necessary to reveal
the optimal doses. The safe dose range was explored by
administrating various doses to a healthy sham animal
before the study. In a pilot study, 50 mg/kg was adminis-
tered to the sham animal but some non-specific negative
effects such as weight loss were found without histo-
logical change in spinal cord. Thus, simvastatin within
the dosage range from the previous pilot study was tried
in the current study. Further study is needed to deter-
mine the optimal dosage for the application of human
spinal cord IR injury. Third, this therapeutic treatment
of simvastatin was effective in rats when administered
immediately after spinal cord ischemia. However, further
studies are needed to better determine whether this
treatment may be amenable for treating human patients.
Conclusion
In summary, 10 mg/kg simvastatin treatment adminis-
tered after spinal cord IR injury significantly improved
the neurobehavioral outcome and preserved normal
motor neuron in rats. The present findings suggest that
simvastatin may be a promising therapeutic agent for
the treatment of spinal cord IR injury.
Fig. 2 Representative microphotographs of the spinal cord from rats in each group. Group (a), group (b), and group (c) show similar features.
Motor neurons suggest ischemic changes with shrunken nuclei and massive pericellular edema. Very few normal-looking motor neurons were
observed. Grey matter shows spongy-like appearance due to marked vacuolization, and many infiltrating cells can be observed in remained gray
matter. On the contrary, motor neurons of Group (d) show no massive vacuolization with minimal degree of pericellular edema. More intact
motor neurons are observed. Group (s): sham group; Group (a): control group; Group (b): 0.5 mg/kg simvastatin group; Group (c): 1 mg/ kg simvastatin
group; Group (d): 10 mg/kg simvastatin group
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